Elevation Oncology, Inc. (ELEV) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Elevation Oncology, Inc.

ELEV

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

22M

Biotechnology

Next Earning date - 01 May 2025

22M

Biotechnology

Next Earning date - 01 May 2025

0.38USD

0.00 ( 1.05%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-63%

Earning Acce

Dist 52w H.

92%

Overview Chart

Quote Panel

Updated April 27, 2025

1W -0.58 % 1M 44.58 % 3M -37.93 % 1Y -90.24 %

Key Metrics

Market Cap
22.26M
Shares Outstanding
59.22M
Share in Float
52.07M
Dividende
0

Earning Date
01 May 2025
Price Target
0.3759
Average Volume
1.53M
Beta
1.668

Range
0.221-4.48
Industry
Biotechnology
Website
https://elevationoncology.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

0.37x

P/B Ratio

0.5

Debt/Equity

0.0%

Net Margin

$-0.8

EPS

How ELEV compares to sector?

P/E Ratio

Fundamentals

Relative Strength

ELEV

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

ELEV

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$0.65

-261%

2025-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Citigroup

downgrade

Previous: Not converted

2025-03-21

Now: Market Perform

Wedbush

downgrade

Previous: Not converted

2025-03-20

Now: Neutral

William Blair

initialise

Previous: Not converted

2025-01-03

Now: Outperform

Piper Sandler

initialise

Previous: Not converted

2024-05-31

Now: Overweight

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.50
vs -0.74

Q2.23

N/A

-0.37
vs -0.86

Q3.23

N/A

-0.25
vs -1.67

Q4.23

N/A

-0.19
vs -0.82

Q1.24

N/A

-0.23
vs -0.50

Q2.24

N/A

-0.18
vs -0.37

Q3.24

N/A

-0.22
vs -0.25

Q4.24

N/A

-0.18
vs -0.19

Q1.25

N/A

-0.19
vs -0.23

Q2.25

N/A

-0.17
vs -0.18

Sales Growth

YoY

Current

Estimates

Q3.22

NA vs NA

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

58K vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 58K

Return on Equity

QoQ

Q1.23

-51%

-0.51
vs -0.39

Q2.23

-14%

-0.14
vs -0.51

Q3.23

-17%

-0.17
vs -0.14

Q4.23

-14%

-0.14
vs -0.17

Q1.24

-14%

-0.14
vs -0.14

Q2.24

-13%

-0.13
vs -0.14

Q3.24

-19%

-0.19
vs -0.13

Q4.24

-17%

-0.17
vs -0.19

Institutionnal Ownership

QoQ

Q1.23

27
vs 26

Q2.23

40
vs 27

48%

Q3.23

40
vs 40

Q4.23

31
vs 40

-22%

Q1.24

64
vs 31

106%

Q2.24

81
vs 64

27%

Q3.24

69
vs 81

-15%

Q4.24

72
vs 69

Earnings Growth

Latest News

prnewswire.com

8 hours ago

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

benzinga.com

11 hours ago

Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

prnewswire.com

13 hours ago

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

zacks.com

14 hours ago

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

prnewswire.com

16 hours ago

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

prnewswire.com

16 hours ago

Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements

Company Description

0.38USD

N/A

0.00x

0.37x

0.5

0.0%

$-0.8

$0.65

Earnings Growth

Latest News

$0.65

Company Description

0.38USD

N/A

0.00x

0.37x

0.5

0.0%

$-0.8